

Title:

Relation of ischemia-modified albumin to disease manifestations and activity in Egyptian patients with Behçet's disease.

Egyptian Rheumatology & Rehabilitation ٢٠١٩, ٤٦:١٠٨-١١٢

Abstract:

Aim of work: To determine level of ischemia-modified albumin (IMA) in patients with Behçet's disease (BD) and to assess its role in disease manifestations and activity. Patients and methods: The study included ٤٨ patients with BD and ٣٨ matched controls. Disease activity was estimated by the BD current activity form. Serum IMA was measured. Results: Mean age of the patients was ٣٣.٨±٧.٩ years. There were ٤٢ males and six females, and the disease duration was ٥٢.٩±٤٨.٨ months. The serum IMA level was significantly increased in the patients with BD (٥٠.٩±١٢.٩ U/ml) compared with the control (٧.٧٦±١.٦ U/ml) ($P<٠.٠٠١$). There was a statistically significant association between IMA level and disease activity, with high mean IMA level among active cases ($P=٠.٠١$). There was no statistically significant association between IMA level and any of other clinical characteristics in patients with BD. Sensitivity and specificity test for IMA level in detection of cases illustrated accuracy of ٩٨.٥% with sensitivity ٩٥.٨% and specificity ٧٨.٩% at cutoff value of ٩.٤ U/ml. Conclusion: There is growing evidence indicating the role of oxidative stress in BD. IMA is accepted as an essential marker of oxidative stress in patients with BD. It has a potential diagnostic value for the detection of the disease. Furthermore, it correlates with the disease activity.